Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : The Microcap Kitchen: Stocks 5¢ to $5 -- Ignore unavailable to you. Want to Upgrade?

To: GARY P GROBBEL who wrote (54987)	7/26/2006 11:05:29 AM
From: GARY P GROBBEL	Read Replies (1) \| Respond to of 120405

CBMX...if bird flu plays take off so should CBMX... From their www site-- CombiMatrix Influenza A Detection System can detect and accurately type influenza A strains in less than four hours. The CombiMatrix Influenza A Detection System accurately identifies hemagglutinin subtypes 1 through 16 and neuraminidase subtypes 1 through 9. In addition to providing very high-resolution information on the genotype of any previously identified strain, the Influenza A Detection System also provides information on novel strains of influenza A produced by rapid mutation or recombination in the genomes which define the serotype of these proteins. The microarray in the detection system, the Influenza A Research Microarray, has been tested and validated against both a representative RNA panel consisting of all influenza A serotypes as well as against amplified genomic material from a limited number of human and animal samples. The Influenza A Research Microarray identifies strains by using standard polymerase chain reaction (PCR) with a universal influenza priming strategy and the use of multiple (tens to hundreds of) unique, sub-type specific probes on the array. The results are read electrochemically by the ElectraSense™ Reader. USE OF THE COMBIMATRIX INFLUENZA A DETECTION SYSTEM The Influenza A Detection System is cost effective, user-friendly and reliable. The Influenza A Detection System offers: The ability to detect all known strains of Influenza A, including differentiating between highly pathogenic and comparatively less pathogenic flu strains. A method that is highly sensitive to mutations in the influenza virus that maximize the likelihood of detecting new strains that have not been previously identified. A novel way to observe mutations and recombination events associated with changes in the genetic makeup of the virus. The ability to identify mixed populations of the flu. RE-USE OF THE COMBIMATRIX INFLUENZA A MICROARRAY CombiMatrix Influenza A Microarrays used in conjunction with the ElectraSense™ Reader can be stripped and re-used for a total of two times, further decreasing the cost of influenza detection. For more information on re-use, please see the information on the CustomArray™ Stripping Kit. MICROARRY SERVICES FOR THE COMBIMATRIX INFLUENZA A MICROARRAY CombiMatrix can also provide Influenza A Typing Services. Inactivated viral RNA samples can be processed at two facilities for rapid identification. KITS AVAILABLE FOR THE INFLUENZA A TYPING SOLUTION ElectraSense™ Influenza A Sub-typing Primers The ElectraSense™ Influenza A Subtyping Primers Kit is used with the CombiMatrix ElectraSense™ platform and CombiMatrix Influenza A Research Microarray. The Influenza A Subtyping Primers Kit contains a common primer for reverse transcription, a common forward PCR primer, and four reverse PCR primer pools, two for HA, and another two for NA genes, and, a special positive hybridization control that is added to the hybridization buffer. ElectraSense™ Detection Kit The ElectraSense™ Influenza A Detection Kit detects and accurately types flu strains with hemagglutinin (HA) subtypes 1 through 15 and neuraminidase (NA) subtypes 1 through 9 during the post-hybridization labeling step of electro-chemical detection. INFLUENZA MICROCARRAY ASSAY-- In the face of concerns over an influenza pandemic, identification of virulent influenza isolates must be obtained quickly for effective responses. Knowledge of the exact strain, origin of the strain and probable characteristics of the virus are critical for surveillance of a disease outbreak and preventing the spread of the disease. Rapid subtype identification of flu is not always straightforward. Simple serological tests on infected individuals are awkward to administer and are an ineffective tool for monitoring viruses undergoing a high rate of mutation or rapid recombination. RT-PCR assays have better sensitivity but are problematic in scenarios where new strains of virus emerge or mixtures of viruses exist. In many situations the identification of the circulating subtype is not sufficient and specific knowledge of the genetic makeup of the virus is required. For example, the avian H5N1 virus ("Bird Flu") has significant potential for further recombination with common human strains (such as H3N2) or other non-human strains common in avian populations (H7 and H9 strains).The H5N1 subtype is also difficult to identify because of the lack of sensitivity and specificity of many of the commercial tests. In addition, genotype Z, the dominant H5N1 virus genotype currently circulating in Vietnam and Thailand, contains a mutation that is associated with resistance to amantadine and rimantadine. Also, because of the high susceptibility in humans and resistance to antibiotics of this isolate, neuraminidase inhibitors must be given within 48 hours of onset of illness to be effective. Thus rapid and specific identification of this subtype and accurate sequence information is crucial for proper treatment. CombiMatrix has also developed a semiconductor-based DNA chip, the CombiMatrix Influenza A Research Microarray, that can detect and accurately type flu strains with hemagglutinin subtypes 1 through 15 and neuraminidase subtypes 1 through 9 using a protocol that requires less than four hours start to finish. In addition to providing very high resolution information on genotype of any given flu strain, it can also provide information on novel strains of flu produced by rapid mutation or recombination between multiple strains of flu. This system is available to the flu researcher as a tool or as a service from CombiMatrix (for research use only at this time). This system is also being developed as a field deployable biodetector using electrochemical techniques for analysis. This chip can be employed as an adjunct to existing technology: to type difficult or ambiguous samples of flu, provide greatly increased confidence in RT-PCR assays or study genetic drift in a flu virus as it moves through a population. The CombiMatrix Influenza A Research Microarray is based on CustomArray 12K™ array format. The specific oligonucleotide probe sets are designed for all known subtypes of hemagglutinin and neuraminidase from the influenza A viruses. The virus genetic material is amplified by PCR, and the resultant target nucleic acid mixture is hybridized to a CombiMatrix Influenza A Research Microarray chip. The enzymatic reactions that are performed on the chip as steps of CombiMatrix Hyb & Seq™ procedure allow for short hybridization times and rapid detection. The whole assay may be performed in less than 4 hours.